ArticleTranslational cancer research2026
Study on the inhibition of thyroid undifferentiated carcinoma metastasis by nanoparticles loaded with EZH2 inhibitor.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anaplastic thyroid carcinoma (ATC) is highly malignant with a poor prognosis. Current treatment methods fail to prolong patients' survival periods, and there is an urgent need to explore new strategies. EZH2 is highly expressed in ATC, and its inhibitors EPZ6438 and GSK343 have anti-cancer potential. However, issues such as insufficient drug concentration at the tumor site, drug resistance, and toxic side effects exist. Bovine serum albumin-chitosan nanoparticles have good biocompatibility, can be slowly degraded, continuously release drugs, and enable targeted drug delivery. This study used bovine serum albumin and chitosan as raw materials to prepare nano-delivery devices loaded with GSK343 and EPZ6438, providing new ideas for clinical treatment. Methods: Two types of nanoparticles were constructed using self-assembly technology, and their characterization and drug release rates were verified. The blood compatibility, Results: Two types of nanoparticles were successfully prepared with good characterization, high drug loading capacity, and encapsulation efficiency, and exhibited a sustained-release effect. Conclusions: Two types of nanoparticles were successfully constructed with good sustained-release, targeting effects, and biosafety. They could improve the therapeutic efficacy and reduce toxic side effects, with GSK343-BSA@CS showing significant effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.